EGFR and cancer: In three out of the five resistant patients, genetic mechanisms of resistance were lost in the absence of the continued selective pressure of EGFR inhibitor treatment, and these cancers were sensitive to a second round of treatment with EGFR inhibitors (Sequist et al., 2011).